HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study

Area of Science:

• Cardiovascular Health
• Pharmacology
• Nutraceuticals

Background:

• Dyslipidemia is a major risk factor for cardiovascular disease.
• Statins are primary treatments, but alternatives are sought.
• Red yeast rice (RYR) is a traditional Chinese ingredient with reported lipid-lowering properties.

Purpose of the Study:

• To evaluate the efficacy of a specific red yeast rice (RYR) product in managing plasma lipid levels.
• To assess the cholesterol-lowering potential of RYR compared to a placebo.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted over 16 weeks.
• Participants (n=42) with LDL-cholesterol between 3.0-6.0 mmol/L and triglycerides <4.5 mmol/L were randomized.
• Subjects received either RYR (HypoCol, 4 capsules/day) or a placebo.

Main Results:

• RYR supplementation led to a statistically significant reduction in LDL-cholesterol by 23.0% (p<0.001).
• Total cholesterol decreased by 15.5% in the RYR group compared to placebo (p<0.001).
• No adverse events were reported, indicating good tolerability.

Conclusions:

• The tested red yeast rice product effectively lowers LDL and total cholesterol levels.
• RYR demonstrates a significant lipid-lowering effect compared to placebo.
• The RYR product was well-tolerated in the studied Caucasian population.